Inflammatix - About the company
Inflammatix is a series E company based in San Francisco (United States), founded in 2016 by Tim Sweeney and Purvesh Khatri. It operates as a Provider of diagnostic solutions for systemic infections. Inflammatix has raised $191M in funding from investors like Khosla Ventures, Think.Health and GSVP. The company has 430 active competitors, including 97 funded and 69 that have exited. Its top competitors include companies like Adaptive Biotechnologies, MeMed and HaystackAnalytics.
Company Details
Provider of diagnostic solutions for systemic infections. Its proprietary technology, based on research from Stanford University, measures gene expression patterns related to the immune system to diagnose sepsis. It provides products such as InSep for acute infection and sepsis tests, ViraBac for acute infection tests, SARC-CoV-2 swabs, etc.
- Website
- inflammatix.com
- Social
- Email ID
- *****@inflammatix.com
- Registered Address
- Burlingame, California
Key Metrics
Founded Year
2016
Location
San Francisco, United States
Stage
Series E
Total Funding
$191M in 13 rounds
Latest Funding Round
Investors
Ranked
19th among 430 active competitors
Employee Count
74 as on Sep 30, 2026
Similar Companies
Legal entities associated with Inflammatix
Inflammatix is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
INFLAMMATIX, INC. CIN: 5984105 , United States, Active | Apr 08, 2021 | - | - | - |
Inflammatix, Inc CIN: 81-2767509 , United States, Active | Dec 31, 2015 | - | 54 (As on Dec 31, 2020) | - |
INFLAMMATIX, INC. CIN: 812767509 , United States, Active | Dec 26, 999 | - | 80 (As on Dec 31, 2024) | - |
Sign up to download Inflammatix's company profile
Inflammatix's funding and investors
Inflammatix has raised a total funding of $191M over 13 rounds. Its first funding round was on May 24, 2017. Its latest funding round was a Series E round on Sep 12, 2024 for $*****. 8 investors participated in its latest round. Inflammatix has 18 institutional investors.
Here is the list of recent funding rounds of Inflammatix:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 12, 2024 | 2813543 | Series E | 3597872 | 5789309 | 4917964 | 3692986 |
Jul 01, 2023 | 2814709 | Grant (prize money) | 8002360 | 4780876 | 5652603 | |
Nov 18, 2021 | 2651865 | Grant (prize money) | 7298649 | 9007366 | 2864043 |
Access funding benchmarks and valuations. Sign up today!View details of Inflammatix's funding rounds and investors
Inflammatix's founders and board of directors
Founder? Claim ProfileThe founders of Inflammatix are Tim Sweeney and Purvesh Khatri.
Here are the details of Inflammatix's key team members:
- Tim Sweeney: Co-Founder & CEO of Inflammatix and founder of 1 other company. Contact Info: 1 email address
- Purvesh Khatri: Co-Founder of Inflammatix and founder of 1 other company. Contact Info: 1 email address
View details of Inflammatix's Founder profiles and Board Members
Inflammatix's employee count trend
Inflammatix has 74 employees as of Sep 26. Here is Inflammatix's employee count trend over the years:
Uncover Inflammatix's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Inflammatix's Competitors and alternates
Top competitors of Inflammatix include Adaptive Biotechnologies, MeMed and HaystackAnalytics. Here is the list of Top 10 competitors of Inflammatix, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Adaptive Biotechnologies 2009, Seattle (United States), Public | Provider of clinical diagnostics, and drug discovery for immune diseases | $419M | 72/100 | |
2nd | Provider of machine learning based diagnostic solutions for infectious diseases | $163M | 69/100 | ||
3rd |  HaystackAnalytics 2018, Mumbai (India), Seed | Provider of genomics technology for personalized clinical decisions | $17.3M | 67/100 | |
4th | PathogenDX 2014, Tucson (United States), Series B | Provider of DNA-based pathogen testing kits | $11.6M | 61/100 | |
5th | Daye 2018, London (United Kingdom), Series A | Manufacturer of period care products and provider of health tests | $19.2M | 60/100 | |
6th |  Agendia 2003, Irvine (United States), Series F | Provider of genomic diagnostic products for the treatment of cancer | $123M | 59/100 | |
7th |  Huwel Life 2015, Hyderabad (India), Series A | Molecular diagnostic solutions and products for the healthcare industry | $5.74M | 59/100 | |
8th |  Oncimmune 2006, Cambridge (United States), Acquired | Immunodiagnostics company developing biomarker platforms for cancer and immune diseases | - | 58/100 | |
9th |  Karius 2014, Redwood City (United States), Series C | Provider of diagnostics for identifying infectious diseases using microbial DNA | $315M | 58/100 | |
10th | Developer of diagnostic kits for pathogen detection and viral load monitoring | - | 57/100 | ||
19th | Inflammatix 2016, San Francisco (United States), Series E | Provider of diagnostic solutions for systemic infections | $191M | 60/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Inflammatix's competitors? Click here to see the top ones
Inflammatix's Investments and acquisitions
Inflammatix has made no investments or acquisitions yet.
Reports related to Inflammatix
Here is the latest report on Inflammatix's geography:
News related to Inflammatix
Filter this listMedia has covered Inflammatix for 1 event in last 1 year, It was about partnerships.
•
Inflammatix Collaborates with University of Nebraska Medical Center to Support Rapid Response to the Hantavirus Outbreak Using TriVerity®PR Newswire•Jun 16, 2026•Inflammatix
•
•
Inflammatix begins trial evaluating mRNA test for patient infection statusclinicaltrialsarena.com•Nov 12, 2024•Inflammatix
•
Inflammatix Adds Three MedTech Industry Veterans to Executive Leadership TeamPR Newswire•Oct 10, 2024•Inflammatix
•
Inflammatix Secures $57 Million to Advance Novel Diagnostic for Patients with Suspected Infections or SepsisPR Newswire•Sep 12, 2024•Inflammatix, Khosla Ventures, think.health, Northpond Ventures and 8 others
•
TriVerity Acute Infection, Sepsis Test Wins FDA Breakthrough StatusMedical Product Outsourcing•Nov 29, 2023•Inflammatix, Triverity
•
Inflammatix Appoints Purvesh Khatri as Chief Scientific OfficerBusiness Wire•Jun 15, 2022•Inflammatix
•
Inflammatix Appoints Dr. Kian Beyzavi as New Board MemberBusiness Wire•Nov 30, 2021•Inflammatix, Cota Capital
•
Inflammatix Receives Additional $12.1M BARDA Funding for MDx Acute Infection Test, SystemGenomeWeb•Nov 18, 2021•Inflammatix, Public Health Emergency
•
Inflammatix Announces Additional $12.1 Million Funding From BARDA for ViraBac EZ Acute Infection TestBusiness Wire•Nov 18, 2021•Inflammatix, Medical Countermeasures
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Inflammatix
Explore our recently published companies
- Pilot-Projects - 2009 founded, Unfunded company
- Nextearthproductions - Unfunded company
- Zakti - Unfunded company
- Valorium - Unfunded company
- Swiftadvisory - Unfunded company
- Winstanley-Consulting - Unfunded company
